
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Leading in Emerging Markets
over 14 years ago
Novartis: LEADing in Emerging Marketsover 14 years ago
How Can We Fix the FDA?over 14 years ago
The Italian's Jobover 14 years ago
Off the Hook? Pharm Exec's Annual Press Auditover 14 years ago
The Maestrosover 14 years ago
The (Life) Science of Digital Connectionsover 14 years ago
Judging a Pill by its Coverover 14 years ago
When Talk is Not So Cheap





